Pulmonology CE Activities


RSS Latest Pulmonology Articles
  • Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia November 30, 2023
    In a randomized trial involving critically ill patients who had undergone mechanical ventilation for 3 days, a 3-day course of inhaled amikacin reduced the burden of ventilator-associated pneumonia.
    Stephan Ehrmann, François Barbier, Julien Demiselle, Jean-Pierre Quenot, Jean-Etienne Herbrecht, Damien Roux, Jean-Claude Lacherade, Mickaël Landais, Philippe Seguin, David Schnell, Anne Veinstein, Philippe Gouin, Sigismond Lasocki, Qin Lu, Gaëtan Beduneau, Martine Ferrandiere, Gaëtan Plantefève, Claire Dahyot-Fizelier, Nader Chebib, Emmanuelle Mercier, Nathalie Heuzé-Vourc’h, Renaud Respaud, Nicolas Gregoire, Denis Garot, Mai-Anh Nay, Ferhat Meziani, Pascal Andreu, Raphaël Clere-Jehl, Noémie Zucman, Marie-Ange Azaïs, Marjorie Saint-Martin, Charlotte Salmon Gandonnière, Dalila Benzekri, Hamid Merdji, Elsa Tavernier, the Reva and CRICS-TRIGGERSEP F-CRIN Research Networks
  • Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions November 30, 2023
    The addition of amivantamab to chemotherapy in patients with advanced non–small-cell lung cancer with EGFR exon 20 insertions resulted in significantly longer progression-free survival.
    Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Baogang Liu, Luis Paz-Ares, Susanna Cheng, Satoru Kitazono, Muthukkumaran Thiagarajan, Jonathan W. Goldman, Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, Jen-Yu Hung, Michael Boyer, Sanjay Popat, Josiane Mourão Dias, Enriqueta Felip, Margarita Majem, Mahmut Gumus, Sang-we Kim, Akira Ono, John Xie, Archan Bhattacharya, Trishala Agrawal, S. Martin Shreeve, Roland E. Knoblauch, Keunchil Park, Nicolas Girard, the PAPILLON Investigators
  • Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer November 30, 2023
    Tarlatamab, a bispecific T-cell engager targeting DLL3 and CD3, led to an objective response in 40% of patients, with 68% alive at 9 months. Cytokine-release syndrome, mainly of low severity, occurred in 51%.
    Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Oscar Juan-Vidal, Sabin Handzhiev, Hiroki Izumi, Jong-Seok Lee, Rafal Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne-Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martinez, Erik S. Anderson, Luis Paz-Ares, the DeLLphi-301 Investigators


View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.